Education
About Us
Working with TipRanks
Follow Us
PepGen Inc. (PEPG)
:PEPG
PEPG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.16 - $19.30
Previous CloseN/A
Volume7.67K
Average Volume (3M)5.42M
Market Cap
$57.87M
Enterprise Value$158.75M
Total Cash (Recent Filing)$49.42M
Total Debt (Recent Filing)$18.66M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Jun 12, 2025EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.84
Shares Outstanding32,692,387
10 Day Avg. Volume485,636
30 Day Avg. Volume5,421,414
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap2.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.68
Forecast
1Y Price Target
$13.25Price Target Upside648.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
EarningsAdditional upside for PEPG shares and their DM1 program is seen as they report additional single dose data and multiple dose data in the future.
Financial PerformanceResults are already reaching levels that have been seen with 6 and 12 months of repeat dosing, which bodes well for what might be seen with repeat dosing.
Safety And EfficacyThe data are very encouraging for the program, with the potential of being best-in-class in the DM1 landscape.
Bears Say
Clinical ChallengesA series of negative updates for PEPG, including two cases of hypomagnesemia, a clinical hold for the other Phase 2 study, and data that just missed their bar of 1% dystrophin expression.
Clinical TrialsThe company also presented early functional outcome data that did not demonstrate a meaningful difference from placebo.
Regulatory ConcernsWe continue to view the DMD clinical holds as a key stock overhang supporting the current Underperform thesis.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PEPG FAQ
What was PepGen Inc.’s price range in the past 12 months?
PepGen Inc. lowest stock price was $1.16 and its highest was $19.30 in the past 12 months.
What is PepGen Inc.’s market cap?
PepGen Inc.’s market cap is $57.87M.
When is PepGen Inc.’s upcoming earnings report date?
PepGen Inc.’s upcoming earnings report date is Jun 12, 2025 which is in 79 days.
How were PepGen Inc.’s earnings last quarter?
PepGen Inc. released its earnings results on Feb 24, 2025. The company reported -$0.68 earnings per share for the quarter, beating the consensus estimate of -$0.814 by $0.134.
Is PepGen Inc. overvalued?
According to Wall Street analysts PepGen Inc.’s price is currently Undervalued.
Does PepGen Inc. pay dividends?
PepGen Inc. does not currently pay dividends.
What is PepGen Inc.’s EPS estimate?
PepGen Inc.’s EPS estimate is -0.72.
How many shares outstanding does PepGen Inc. have?
PepGen Inc. has 32,692,387 shares outstanding.
What happened to PepGen Inc.’s price movement after its last earnings report?
PepGen Inc. reported an EPS of -$0.68 in its last earnings report, beating expectations of -$0.814. Following the earnings report the stock price went up 67.153%.
Which hedge fund is a major shareholder of PepGen Inc.?
Currently, no hedge funds are holding shares in PEPG
---
PepGen Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.25 (648.59% Upside)
$13.25 (648.59% Upside)
Blogger Sentiment
Bullish
PEPG Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 580.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.8%
Last 30 Days ▲ 9.6%
Last 30 Days ▲ 9.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.03%
12-Months-Change
Fundamentals
Return on Equity
-79.26%
Trailing 12-Months
Asset Growth
5.47%
Trailing 12-Months
Company Description
PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
---
PEPG Stock 12 Month Forecast
Average Price Target
$13.25
▲(648.59% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
PTC Therapeutics
―
Wave Life Sciences
―
Avidity Biosciences
―
Best Analysts Covering PEPG
1 Year
1 Year Success Rate
6/14 ratings generated profit
1 Year Average Return
-15.04%
reiterated a buy rating 29 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -15.04% per trade.
---